Blow-off or not, progress toward S&P 7000 is ongoing -- so let's see if small caps extend more. Structurally dips at least for now should be within the uptrend context.

Short interest on Viking Therapeutics spikes to a five-year high above 30% while shares crater 36% as oral GLP-1 Phase 2 study fails to clear high expectations. Plus WULF, MLTX, SMR.